<DOC>
	<DOCNO>NCT00796835</DOCNO>
	<brief_summary>The purpose study evaluate dose proportionality 3- , 6- , 9- , 12- , 15-mg tablet ER OROS paliperidone . Additionally , safety tolerability treatment healthy volunteer assess .</brief_summary>
	<brief_title>A Dose-proportionality Study Five Tablet Strengths ER OROS Paliperidone</brief_title>
	<detailed_description>This study design single-center , open-label , randomize , 5 treatment-period , crossover study healthy male adult . The study consist screen phase open-label treatment phase volunteer receive 5 treatment study drug random order separate washout period 10 14 day . Treatments consist single oral dose : A ) 1 tablet contain 3 mg ER OROS paliperidone ; B ) 1 tablet contain 6 mg ER OROS paliperidone ; C ) 1 tablet contain 9 mg ER OROS paliperidone ; D ) 1 tablet contain 12 mg ER OROS paliperidone ; E ) 1 tablet contain 15 mg ER OROS paliperidone . All treatment administer overnight fast . Volunteers remain bed 4 hour dose strongly advise remain bed 36 hour . Five different ER OROS paliperidone tablet strength ( 3 , 6 , 9 , 12 , 15 mg ) develop intent market . Since ER OROS paliperidone extend release formulation , study design show dose-proportional pharmacokinetics dose strength . Safety tolerability monitor throughout study . Treatments consist single oral dose : A ) 1 tablet contain 3 mg ER OROS paliperidone ; B ) 1 tablet contain 6 mg ER OROS paliperidone ; C ) 1 tablet contain 9 mg ER OROS paliperidone ; D ) 1 tablet contain 12 mg ER OROS paliperidone ; E ) 1 tablet contain 15 mg ER OROS paliperidone</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Body Mass Index ( weight [ kg ] /height [ m² ] ) 18 28 kg/m² , inclusive Normotensive supine ( 5 minute ) blood pressure range 100 140 mmHg systolic , inclusive , 60 90 mmHg diastolic , inclusive Healthy basis prestudy physical examination , medical history , ECG , laboratory result serum chemistry , hematology urinalysis perform within 21 day first dose . If result serum chemistry , hematology urinalysis test within laboratory 's reference range volunteer include investigator judge deviation clinically significant For renal function test , value must within normal laboratory reference range . Recent history alcohol substance abuse , positive test result urine drug screen screen upon admittance test facility positive result alcohol breath test upon admittance test facility Relevant history presence cardiovascular ( include myocardial infarct cardiac arrhythmia ) , respiratory , neurologic ( include seizure ) , psychiatric , renal , hepatic , gastrointestinal ( include surgery , severe gastrointestinal narrowing , malabsorption problem ) , endocrine , hematologic immunologic disease History cancer , exception basal cell carcinoma At screening , sustain decrease &gt; 20 mmHg systolic blood pressure decrease &gt; 10 mmHg diastolic blood pressure stand least 2 minute associated increase &gt; 15 beat per minute ( bpm ) heart rate Bradycardia ( heart rate &lt; 50 bpm ) determine screen ECG History positive result serology test ( hepatitis B , C , HIV ) History smoking use nicotinecontaining substance within last 2 month , determine medical history and/or volunteer 's verbal report . Volunteers must agree refrain use throughout study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Mood disorder</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>ER OROS Paliperidone</keyword>
</DOC>